Filetype
21 January 2025 14:15 to 15:00 | Seminar A Computational Chemistry seminar by Dr. Lucrezia Catapano, University of Cambridge, United KingdomTitle: will come About the eventLocation:Lecturehall KC:FContact:esko [dot] oksanen [at] compchem [dot] lu [dot] se Save the event to your calendar
https://www.compchem.lu.se/calendar/computational-chemistry-lucrezia-catapano - 2025-07-13
4 February 2025 14:15 to 15:00 | Seminar A Computational Chemistry seminar by PhD David Ribar, Computational Chemistry, Lund UniversityTitle: will come About the eventLocation:Lecturehall KC:FContact:ulf [dot] ryde [at] teokem [dot] lu [dot] se Save the event to your calendar
https://www.compchem.lu.se/calendar/computational-chemistry-david-ribar - 2025-07-13
18 February 2025 14:15 to 15:00 | Seminar A Computational Chemistry seminar by Postdoc Petteri Vainikka , Center for analysis and synthesis (CAS), Lund UniversityTitle: A coarse-grained approach to novel solvents About the eventLocation:Lecturehall KC:FContact:ulf [dot] ryde [at] compchem [dot] lu [dot] se Save the event to your calendar
https://www.compchem.lu.se/calendar/computational-chemistry-petteri-vainikka - 2025-07-13
25 February 2025 14:15 to 15:00 | Seminar Seminar by Postdoc Gyula Hoffka, Computational Chemistry. Title: TBA About the eventLocation:Lecturehall KC:LContact:ulf [dot] ryde [at] compchem [dot] lu [dot] se Save the event to your calendar
https://www.compchem.lu.se/calendar/gyula-hoffka-computational-chemistry - 2025-07-13
Welcome to CREATE Health Our vision: To contribute with innovative diagnostics and therapeutic solutions not for coming generations but for today's CREATE Health aims to provide individualized and improved therapeutic strategies, based on our ability to determine which patient will benefit from a particular treatment. CREATE Health provides solutions to clinical problems by developing innovative d
https://www.createhealth.lth.se/start - 2025-07-13
Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth[dot]se) Board Carl BorrebaeckChairman of the Boardcarl [dot] borrebaeck [at] immun [dot] lth [dot] se (carl[dot]borrebaeck[at]immun[d
https://www.createhealth.lth.se/about/centre-management-and-board - 2025-07-13
Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.
https://www.createhealth.lth.se/about/recruitment - 2025-07-13
Please wait...
https://www.createhealth.lth.se/about/principle-investigators - 2025-07-13
Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ
https://www.createhealth.lth.se/research-and-innovation/ongoing-collaborations-and-partners - 2025-07-13
CantargiaCantargia AB was founded in 2009/2010 by Thoas Fioretos and Marcus Järås (Lund University), Kjell Sjöström (Innovagen), and by LU Bioscience. The company specializes in antibody-based cancer therapy. After initially focusing on treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC), new antibodies designed for the treatment of autoimmune and inflammatory diseases hav
https://www.createhealth.lth.se/research-and-innovation/spin-outs - 2025-07-13
The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology
https://www.createhealth.lth.se/canfaster - 2025-07-13
The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &
https://www.createhealth.lth.se/canfaster/publications - 2025-07-13
Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1sNext generation immuno-oncological targets for cancer therapySubtype-dependent biomarkers for systemic therapy in bladder cancer
https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects - 2025-07-13
Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas
Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su
Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye
Address Medicon Village - Building 406Sheelevägen 2 223 81 LundSweden Are you applying for a position? For general questions regarding the call, contact us at:canfaster-postdoc [at] immun [dot] lth [dot] se (canfaster-postdoc[at]immun[dot]lth[dot]se) DirectorSara Ek, Professorsara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se)+46-46-222-3824 Research coordinatorJana H
https://www.createhealth.lth.se/canfaster/contact - 2025-07-13
Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden
https://www.createhealth.lth.se/contact - 2025-07-13
Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solutions, which can be implemented into the clinic with much shorter lead times. CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and pr
https://www.createhealth.lth.se/about - 2025-07-13
Focus AreasPsychological Resilience in Cancer, Bioinformatics and AIOngoing Collaborations and partnersCantargia, IMMUNOVIA, Paindrainer, Akuru PharmaSpin OutsWorking together is an integral part of CREATE Health’s DNA
https://www.createhealth.lth.se/research-and-innovation - 2025-07-13
